Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

February 2022 | 50 pages | ID: B7F037BD8AA1EN
Global Markets Direct

Abstracts

Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Beta Nerve Growth Factor (Beta NGF or NGF) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 1, 2, 5 and 2 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology, Dermatology, Hematological Disorders, Immunology and Musculoskeletal Disorders which include indications Pain, Cancer Pain, Osteoarthritis Pain, Amyotrophic Lateral Sclerosis, Back Pain, Cardiac Arrest, Diabetic Neuropathic Pain, Glaucoma, Keratitis, Lung Transplant Rejection, Myocardial Infarction, Optic Nerve Injury, Osteoarthritis, Parkinson's Disease, Peripheral Nerve Injury, Post-Operative Pain, Pressure Ulcers, Retinitis Pigmentosa (Retinitis), Sicca Syndrome (Sjogren) and Sickle Cell Disease.

Furthermore, this report also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
• The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
• The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF) Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Beta Nerve Growth Factor (Beta NGF or NGF) - Overview
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development
Akeso Inc
AstraZeneca Plc
Chengdu Easton Biopharmaceuticals Co Ltd
Dartsbio Pharmaceutical (Guangdong) Co Ltd
Fujimoto Pharmaceutical Corp
MimeTech Srl
Regeneron Pharmaceuticals Inc
Shandong Boan Biotechnology Co Ltd
Staidson BioPharma Inc
Zhuhai Trinomab Biotechnology Co Ltd
Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles
AK-115 - Drug Profile
Product Description
Mechanism Of Action
DS-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
EP-9001A - Drug Profile
Product Description
Mechanism Of Action
fasinumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
MEDI-7352 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody to Target NGF beta in Chronic Back Pain, Cancer Pain and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
MT-2 - Drug Profile
Product Description
Mechanism Of Action
History of Events
RBM-004 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile
Product Description
Mechanism Of Action
TNM-009 - Drug Profile
Product Description
Mechanism Of Action
TNM-010 - Drug Profile
Product Description
Mechanism Of Action
TNM-011 - Drug Profile
Product Description
Mechanism Of Action
udonitrectag - Drug Profile
Product Description
Mechanism Of Action
History of Events
Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products
Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones
Featured News & Press Releases
Feb 10, 2022: Approval of clinical trial of NGF monoclonal antibody (AK115) for the treatment of pain (including cancer pain) firstly introduced by Akeso in the field of pain
Jan 01, 2021: Congratulations to DartsBio Pharmaceutical for analgesic DS002 injection approved for clinical trial by NMPA
Dec 05, 2018: Recordati receives orphan drug designation for its investigational treatment for neurotrophic keratitis
Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints
Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis
Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs
May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain
Dec 27, 2010: FDA Halts Development Of Regeneron’s Pain Drug
May 12, 2010: Regeneron Provides Initial Data On REGN475
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Akeso Inc, 2022
Pipeline by AstraZeneca Plc, 2022
Pipeline by Chengdu Easton Biopharmaceuticals Co Ltd, 2022
Pipeline by Dartsbio Pharmaceutical (Guangdong) Co Ltd, 2022
Pipeline by Fujimoto Pharmaceutical Corp, 2022
Pipeline by MimeTech Srl, 2022
Pipeline by Regeneron Pharmaceuticals Inc, 2022
Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
Pipeline by Staidson BioPharma Inc, 2022
Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022